Alerts will be sent to your verified email
Verify Email
PPLPHARMA
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
15.43 % | n/a | n/a |
|
R&D as a % of Total Sales
|
0.14 % | 1.57 % | 1683.57 % |
|
Financials
|
|||
|
5 yr Average ROE
|
3.82 % | 27.26 % | -65.97 % |
|
5yr average Equity Multiplier
|
1.94 | 1.3 | 1.69 |
|
5yr Average Asset Turnover Ratio
|
0.55 | 0.61 | 0.05 |
|
5yr Avg Net Profit Margin
|
3.51 % | 33.51 % | -798.21 % |
|
Price to Book
|
3.22 | 22.49 | 56.52 |
|
P/E
|
267.15 | 140.45 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-19.3 Days | 70.98 Days | 54.79 Days |
|
Inventory Days
|
70.13 Days | 76.62 Days | 10.88 Days |
|
Days Receivable
|
77.05 Days | 42.46 Days | 71.91 Days |
|
Days Payable
|
159.9 Days | 85.69 Days | 3.38 Days |
|
5yr Average Interest Coverage Ratio
|
2.86 | 47.81 | -373.47 |
|
5yr Avg ROCE
|
6.75 % | 32.61 % | -67.21 % |
|
5yr Avg Operating Profit Margin
|
15.15 % | 43.1 % | -890.08 % |
|
5 yr average Debt to Equity
|
0.62 | 0.09 | 0.01 |
|
5yr CAGR Net Profit
|
-35.79 % | -1.08 % | 17.38 % |
|
5yr Average Return on Assets
|
2.03 % | 20.57 % | -37.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.86 % | 66.41 % | 70.27 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.07 % | 6.41 % | 5.29 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
11.78 % | 2.58 % | 0.0 |
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Services Break-Up
|
Services Break-Up
|
-
|
-
|